P70S6K 1 regulation of angiogenesis through VEGF and HIF-1α expression

被引:73
作者
Bian, Chuan-Xiu [2 ]
Shi, Zhumei [2 ]
Meng, Qiao [1 ]
Jiang, Yue [1 ]
Liu, Ling-Zhi [1 ]
Jiang, Bing-Hua [1 ,2 ]
机构
[1] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA
[2] Nanjing Med Univ, Ctr Canc, Dept Pathol, Nanjing 210029, Peoples R China
基金
中国国家自然科学基金;
关键词
p70S6K1; VEGF; HIF-1; Tumor angiogenesis; siRNA; ENDOTHELIAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL; 3-KINASE; MAMMALIAN TARGET; OVARIAN-CANCER; SIGNALING PATHWAY; KINASE-ACTIVITY; MTOR; RAPAMYCIN; CELLS; TRANSLATION;
D O I
10.1016/j.bbrc.2010.06.080
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The 70 kDa ribosomal S6 kinase 1 (p70S6K1), a downstream target of phosphoinositide 3-kinase (PI3K) and ERK mitogen-activated protein kinase (MAPK), is an important regulator of cell cycle progression, and cell proliferation. Recent studies indicated an important role of p70S6K1 in PTEN-negative and AKT-overexpressing tumors. However, the mechanism of p70S6K1 in tumor angiogenesis remains to be elucidated. In this study, we specifically inhibited p70S6K1 activity in ovarian cancer cells using vector-based small interfering RNA (siRNA) against p70S6K1. We found that knockdown of p70S6K1 significantly decreased VEGF protein expression and VEGF transcriptional activation through the HIF-1 alpha binding site at its enhancer region. The expression of p70S6K1 siRNA specifically inhibited but HIF-1 alpha, but not HIF-1 beta protein expression. We also found that p70S6K1 down-regulation inhibited ovarian tumor growth and angiogenesis, and decreased cell proliferation and levels of VEGF and HIF-1 alpha expression in tumor tissues. Our results suggest that p70S6K1 is required for tumor growth and angiogenesis through HIF-1 alpha and VEGF expression, providing a molecular mechanism of human ovarian cancer mediated by p70S6K1 signaling. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:395 / 399
页数:5
相关论文
共 34 条
[1]   AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth [J].
Altomare, DA ;
Wang, HQ ;
Skele, KL ;
De Rienzo, A ;
Klein-Szanto, AJ ;
Godwin, AK ;
Testa, JR .
ONCOGENE, 2004, 23 (34) :5853-5857
[2]   A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt [J].
Aoki, M ;
Blazek, E ;
Vogt, PK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (01) :136-141
[3]  
Burroughs KD, 2003, MOL CANCER RES, V1, P312
[4]  
Byrne AT, 2003, CLIN CANCER RES, V9, P5721
[5]   Serum vascular endothelial growth factor in epithelial ovarian neoplasms: Correlation with patient survival [J].
Chen, CA ;
Cheng, WF ;
Lee, CN ;
Chen, TM ;
Kung, CCS ;
Hsieh, FJ ;
Hsieh, CY .
GYNECOLOGIC ONCOLOGY, 1999, 74 (02) :235-240
[6]   PDGF-DEPENDENT AND INSULIN-DEPENDENT PP70(S6K) ACTIVATION MEDIATED BY PHOSPHATIDYLINOSITOL-3-OH KINASE [J].
CHUNG, JK ;
GRAMMER, TC ;
LEMON, KP ;
KAZLAUSKAS, A ;
BLENIS, J .
NATURE, 1994, 370 (6484) :71-75
[7]   Peritoneal VEGF burden as a predictor of cytoreductive surgery outcome in women with epithelial ovarian cancer [J].
Diniz Bizzo, Solange Maria ;
Meira, Debora Dummer ;
Lima, Jose Marinaldo ;
Mororo, Janio da Silva ;
Casali-da-Rocha, Jose Claudio ;
Faria Ornellas, Maria Helena .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2010, 109 (02) :113-117
[8]   Mechanism of action of the immunosuppressant rapamycin [J].
Dumont, FJ ;
Su, QX .
LIFE SCIENCES, 1995, 58 (05) :373-395
[9]   Integrinαvβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis [J].
Eliceiri, BP ;
Klemke, R ;
Strömblad, S ;
Cheresh, DA .
JOURNAL OF CELL BIOLOGY, 1998, 140 (05) :1255-1263
[10]   Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression [J].
Fingar, DC ;
Blenis, J .
ONCOGENE, 2004, 23 (18) :3151-3171